Literature DB >> 11025794

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease.

J Charrow1, H C Andersson, P Kaplan, E H Kolodny, P Mistry, G Pastores, B E Rosenbloom, C R Scott, R S Wappner, N J Weinreb, A Zimran.   

Abstract

BACKGROUND: The Gaucher Registry, the largest database of patients with Gaucher disease (GD) worldwide, was initiated to better delineate the progressive nature of the disorder and determine optimal therapy. This report describes the demographic and clinical characteristics of 1698 patients with GD before they received enzyme replacement therapy.
METHODS: Physicians worldwide who treat patients with GD were invited to submit prospective and retrospective data for an ongoing registry, using standardized data collection forms, for central processing and review.
RESULTS: Most patients were from the United States (45%) and Israel (17%), but patients are from 38 countries. Most (94%) had type 1 GD, fewer than 1% had type 2, and 5% had type 3. Mutant allele frequency data, available for 45% of patients, showed the most common alleles to be N370S (53%), L444P (18%), 84GG (7%), and IVS2+1 (2%). Twenty-five percent of L444P homozygotes (13 of 52 patients) had type 1 GD phenotype. Mean age at diagnosis in patients with the N370S/N370S genotype was 27.2 years (SD, 19.7 years); in L444P/L444P patients, 2. 3 years (SD, 3.2 years). Histories of bone pain and radiological bone disease were reported by 63% and 94% of patients, respectively; both were more likely in asplenic patients than in patients with spleens. Mean spleen and liver volumes were 19.8 and 2.0 multiples of normal, respectively. Anemia and thrombocytopenia were present in 64% and 56%, respectively. Thrombocytopenia was present in 13% of asplenic patients.
CONCLUSIONS: The Gaucher Registry permits a comprehensive understanding of the clinical spectrum of GD because of the uniquely large sample size. The Registry will be useful in evaluating the effects of specific therapies in GD and the possible influences of environment, ethnicity, and genotype on the natural history of the disorder.

Entities:  

Mesh:

Year:  2000        PMID: 11025794     DOI: 10.1001/archinte.160.18.2835

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  145 in total

1.  Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.

Authors:  Ying Sun; Benjamin Liou; You-Hai Xu; Brian Quinn; Wujuan Zhang; Rick Hamler; Kenneth D R Setchell; Gregory A Grabowski
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

2.  Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health.

Authors:  S R Mastaglia; N P Watman; B Oliveri
Journal:  Osteoporos Int       Date:  2010-06-10       Impact factor: 4.507

3.  The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG).

Authors:  P Chérin; C Rose; C de Roux-Serratrice; D Tardy; D Dobbelaere; B Grosbois; E Hachulla; R Jaussaud; R-M Javier; E Noël; P Clerson; A Hartmann
Journal:  J Inherit Metab Dis       Date:  2010-06-02       Impact factor: 4.982

Review 4.  Radiological aspects of Gaucher disease.

Authors:  Robert Katz; Tom Booth; Rikin Hargunani; Peter Wylie; Brian Holloway
Journal:  Skeletal Radiol       Date:  2010-07-25       Impact factor: 2.199

Review 5.  Revised recommendations for the management of Gaucher disease in children.

Authors:  Paige Kaplan; Hagit Baris; Linda De Meirleir; Maja Di Rocco; Amal El-Beshlawy; Martina Huemer; Ana Maria Martins; Ioana Nascu; Marianne Rohrbach; Lynne Steinbach; Ian J Cohen
Journal:  Eur J Pediatr       Date:  2012-07-08       Impact factor: 3.183

6.  Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International Registry.

Authors:  David C Dale; Audrey Anna Bolyard; Laurie A Steele; Cornelia Zeidler; Karl Welte
Journal:  Curr Opin Hematol       Date:  2020-01       Impact factor: 3.284

7.  Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?

Authors:  Benjamin Fedida; Sébastien Touraine; Jerôme Stirnemann; Nadia Belmatoug; Jean-Denis Laredo; David Petrover
Journal:  Eur Radiol       Date:  2015-04-16       Impact factor: 5.315

8.  Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease.

Authors:  Manoj Kumar Pandey; Reena Rani; Wujuan Zhang; Kenneth Setchell; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2012-04-30       Impact factor: 4.797

9.  Cauda equina syndrome due to an intra-dural sacral cyst in type-1 Gaucher disease.

Authors:  Abderrahmane Hamlat; Stephan Saikali; Mohamed Lakehal; Michèle Pommereuil; Xavier Morandi
Journal:  Eur Spine J       Date:  2003-12-20       Impact factor: 3.134

10.  Genetic counseling throughout the life cycle.

Authors:  Leslie J Ciarleglio; Robin L Bennett; Jennifer Williamson; Jessica B Mandell; Joan H Marks
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.